DILUTION of EQUITY, TWO KEY EMPLOYEES LEFT, and PERFORMANCE CRITERIA NOT MET by 50%.
All the while potentially diluting the shares from 38 million outstanding to 100,000,000 outstanding which is a 62% dilution. This means the stock is at $3.55 today. If you subtract out 62% the stock price it should be selling for $2.20 less than it is posted or $1.35 p/s.
The doctor left and was replaced
The CFO left and was replaced
During the performance reviews that were disclosed in the SEC filing many people only hit 50% of their objectives for their bonuses
The stock has tanked over the past two years
The decision was made to not take the FDA recommendation and the management opted for a white paper study now eight months later they want to resubmit to alter the study
In Jesi Stracham Facebook post, she was patient two she states the following (facebook jesi stracham.com)
Jesi Stracham
April 7 at 4:11pm ·
For the last two years I was told by medical professionals and peers not to get my hopes up because I would never walk again. Ken Bryant assisted in changing my outlook on my future, and for the first time in my life I can say with confidence, I will walk again. It's looking a bit taller ??
#teamJESI
#thisgirlcan
#wheelwithme
The new objective is to get all of the procedures complete in 2017 and submittal and approval in 2018. Isn't that much later than originally stated.
Yet the executives are asking for a pay raise to be voted on in the annual meeting. Are you kidding me. There are executives making extremely high compensation levels yet miss their performance benchmarks.
The executives are asking for more time to complete the study.
While I believe the executives are trying that does not set aside the fact that this is business and not friendship, objectives were missed, dilution is imminent, and the time line has been pushed out yet one more time. This stock is tremendously overpriced.
